Keywords: Contrast Agents, Contrast Agents, Blood Relaxivity, Signal Modeling
Motivation: The R1, R2 and R2* relaxivity behavior of gadopiclenol in blood is unknown.
Goal(s): Verify gadopiclenol blood R1 relaxivity behaves according to previously established water exchange principles and measure its blood R2 and R2* relaxivity.
Approach: The R1, R2 and R2* of gadopiclenol were measured in plasma and doped human blood at 1.5 and 3T.
Results: Gadopiclenol’s high plasma R1 relaxivity is confirmed, and it behaves in blood as predicted. Blood R2 and R2* relaxivity are greater than those of other currently marketed gadolinium-based contrast agents (GBCAs).
Impact: Different GBCAs have different relaxivity properties in blood. Knowledge of these properties allows for accurate modeling and optimization of exams such as CE-MRA, 1st pass arterial phase imaging and perfusion.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords